Prana's Phase II Huntington's disease study meets primary endpoint

Australia-based Prana Biotechnology has reported that its Reach2HD Phase II clinical trial investigating PBT2 as a treatment for Huntington disease succeeded in meeting the primary endpoint of the study.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news